AU2020266170B2 - Process for preparing XPO1 inhibitors and intermediates for use in the preparation of XP01 inhibitors - Google Patents

Process for preparing XPO1 inhibitors and intermediates for use in the preparation of XP01 inhibitors

Info

Publication number
AU2020266170B2
AU2020266170B2 AU2020266170A AU2020266170A AU2020266170B2 AU 2020266170 B2 AU2020266170 B2 AU 2020266170B2 AU 2020266170 A AU2020266170 A AU 2020266170A AU 2020266170 A AU2020266170 A AU 2020266170A AU 2020266170 B2 AU2020266170 B2 AU 2020266170B2
Authority
AU
Australia
Prior art keywords
structural formula
compound represented
iii
vii
conditions suitable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020266170A
Other languages
English (en)
Other versions
AU2020266170A1 (en
Inventor
Brian Clinton AUSTAD
David G. Roe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Karyopharm Therapeutics Inc
Original Assignee
Karyopharm Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Karyopharm Therapeutics Inc filed Critical Karyopharm Therapeutics Inc
Publication of AU2020266170A1 publication Critical patent/AU2020266170A1/en
Application granted granted Critical
Publication of AU2020266170B2 publication Critical patent/AU2020266170B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2020266170A 2019-05-01 2020-05-01 Process for preparing XPO1 inhibitors and intermediates for use in the preparation of XP01 inhibitors Active AU2020266170B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962841649P 2019-05-01 2019-05-01
US62/841,649 2019-05-01
PCT/US2020/031124 WO2020223678A1 (en) 2019-05-01 2020-05-01 Process for preparing xpo1 inhibitors and intermediates for use in the preparation of xp01 inhibitors

Publications (2)

Publication Number Publication Date
AU2020266170A1 AU2020266170A1 (en) 2021-11-25
AU2020266170B2 true AU2020266170B2 (en) 2026-02-26

Family

ID=70802955

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020266170A Active AU2020266170B2 (en) 2019-05-01 2020-05-01 Process for preparing XPO1 inhibitors and intermediates for use in the preparation of XP01 inhibitors

Country Status (14)

Country Link
US (1) US12479806B2 (cg-RX-API-DMAC7.html)
EP (1) EP3962898A1 (cg-RX-API-DMAC7.html)
JP (2) JP7630444B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220004142A (cg-RX-API-DMAC7.html)
CN (1) CN114040909B (cg-RX-API-DMAC7.html)
AU (1) AU2020266170B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021021706A2 (cg-RX-API-DMAC7.html)
CA (1) CA3135712A1 (cg-RX-API-DMAC7.html)
CR (1) CR20210590A (cg-RX-API-DMAC7.html)
IL (1) IL287673B1 (cg-RX-API-DMAC7.html)
MA (1) MA55808A (cg-RX-API-DMAC7.html)
MX (1) MX2021013211A (cg-RX-API-DMAC7.html)
SG (1) SG11202111993SA (cg-RX-API-DMAC7.html)
WO (1) WO2020223678A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114040909B (zh) 2019-05-01 2025-06-03 卡尔约药物治疗公司 用于制备xpo1抑制剂以及用于制备xp01抑制剂的中间体的方法
JP2021048976A (ja) * 2019-09-24 2021-04-01 株式会社ユニバーサルエンターテインメント 遊技機
CN112679477B (zh) * 2020-12-17 2021-10-26 佛山奕安赛医药科技有限公司 塞利尼索及其中间体的制备方法
CN116514773B (zh) * 2023-04-24 2024-12-03 重庆汉佩生物科技有限公司 一种Verdinexor(KPT-335)及其盐酸盐的合成方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013170068A2 (en) * 2012-05-09 2013-11-14 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
WO2014205393A1 (en) * 2013-06-21 2014-12-24 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
WO2016025904A1 (en) * 2014-08-15 2016-02-18 Karyopharm Therapeutics Inc. Polymorphs of selinexor
WO2017118940A1 (en) * 2016-01-08 2017-07-13 Dr. Reddy's Laboratories Limited Solid forms of selinexor and process for their preparation
WO2018129227A1 (en) * 2017-01-05 2018-07-12 Watson Laboratories Inc. Novel crystalline forms of selinexor and process for their preparation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2542089B1 (en) 2010-03-05 2017-01-18 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
EP2665362B1 (en) 2011-01-17 2016-03-30 Karyopharm Therapeutics, Inc. Olefin containing nuclear transport modulators and uses thereof
EP4234545A3 (en) 2011-07-29 2023-09-06 Karyopharm Therapeutics Inc. Hydrazide containing nuclear transport modulators and uses thereof
JP6006794B2 (ja) 2011-07-29 2016-10-12 カリオファーム セラピューティクス,インコーポレイテッド 核内輸送調節因子およびその使用
EP2968278B8 (en) 2013-03-15 2019-05-22 Karyopharm Therapeutics Inc. Methods of promoting wound healing using crm1 inhibitors
ME03421B (me) 2013-06-21 2020-01-20 Karyopharm Therapeutics Inc 1,2,4-triazoli kao modulatori nuklearnog transporta i njihova upotreba
US10526295B2 (en) 2015-12-31 2020-01-07 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
EP3397634A1 (en) 2015-12-31 2018-11-07 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
CN114040909B (zh) 2019-05-01 2025-06-03 卡尔约药物治疗公司 用于制备xpo1抑制剂以及用于制备xp01抑制剂的中间体的方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013170068A2 (en) * 2012-05-09 2013-11-14 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
WO2014205393A1 (en) * 2013-06-21 2014-12-24 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
WO2016025904A1 (en) * 2014-08-15 2016-02-18 Karyopharm Therapeutics Inc. Polymorphs of selinexor
WO2017118940A1 (en) * 2016-01-08 2017-07-13 Dr. Reddy's Laboratories Limited Solid forms of selinexor and process for their preparation
WO2018129227A1 (en) * 2017-01-05 2018-07-12 Watson Laboratories Inc. Novel crystalline forms of selinexor and process for their preparation

Also Published As

Publication number Publication date
AU2020266170A1 (en) 2021-11-25
US20220242832A1 (en) 2022-08-04
CR20210590A (es) 2022-03-11
JP2025072490A (ja) 2025-05-09
JP2022531576A (ja) 2022-07-07
JP7850834B2 (ja) 2026-04-23
CA3135712A1 (en) 2020-11-05
WO2020223678A1 (en) 2020-11-05
US12479806B2 (en) 2025-11-25
MX2021013211A (es) 2022-03-11
SG11202111993SA (en) 2021-11-29
IL287673B1 (en) 2026-01-01
EP3962898A1 (en) 2022-03-09
MA55808A (fr) 2022-03-09
JP7630444B2 (ja) 2025-02-17
CN114040909A (zh) 2022-02-11
IL287673A (en) 2021-12-01
BR112021021706A2 (pt) 2022-04-19
KR20220004142A (ko) 2022-01-11
CN114040909B (zh) 2025-06-03

Similar Documents

Publication Publication Date Title
AU2020266170B2 (en) Process for preparing XPO1 inhibitors and intermediates for use in the preparation of XP01 inhibitors
EP3645518B1 (en) Synthesis of omecamtiv mecarbil
JP6873053B2 (ja) タンパク質脱アセチル化阻害剤の製造方法
CN102131787B (zh) 制备2-卤代-4-硝基咪唑及其中间体的方法
CN101506152B (zh) 1-(3,4-二氯苄基)-5-辛基双胍或其盐的制备方法
TWI233924B (en) Process for trans-4-amino-1-cyclohexane carboxylic acid derivatives
JP2021515018A (ja) 可溶性グアニル酸シクラーゼ刺激薬を調製するための方法
JP7600219B2 (ja) サリチルアミンアセテートの調製方法
JP5078211B2 (ja) 複素環式化合物の製造方法
JP2009525964A (ja) 6,7−ジヒドロ−5H−イミダゾ[1,2−a]イミダゾール−3−スルホン酸アミドの合成
CN114436991A (zh) 一种2-氨基噻唑类化合物的合成方法
JP2022543057A (ja) 結晶形iiのソタグリフロジンを調製する方法
JP2026513413A (ja) 4-アミノインダンの製造方法およびジヒドロインデニル-ピラゾロ[3,4-b]ピリジンアミン化合物の製造方法
EA052667B1 (ru) Синтез дироксимелфумарата
CN109862890A (zh) 纯化cenicriviroc和用于制备cenicriviroc的纯化中间体
CN115368283A (zh) 一种手性结构或非手性结构的顺式-3-氟-4-羟基吡咯烷及其衍生物的制备方法
CN101263128B (zh) 1,2-苯并异噁唑-3-乙酸的磺化方法
TW202219027A (zh) 取代的丙烯酸酯化合物的製備
IL263091A (en) Method for the production of heterocyclic compounds
HK40025477A (en) Synthesis of omecamtiv mecarbil
HK40025477B (en) Synthesis of omecamtiv mecarbil
JPH09216886A (ja) トリアゾロピリダジン誘導体の製造法
JP2002138086A (ja) アルキルオキシアミノフラノン誘導体の製造方法
JPWO2000078722A1 (ja) 医薬品中間体化合物の製造方法